Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Med Oncol. 2022 May 17;39(5):84. doi: 10.1007/s12032-022-01681-4.
It has been recently revealed that Histone Deacetylase (HDAC) 3, a unique member of the HDACs family, can trigger and progress cancers by alternation in genes expression and proteins activity. Epigenetic modifications by HDACs have been studied well in various cancer cells. Recent studies have focused on the HDAC enzymes as a possible target in cancer therapy. There are significant documents on upregulation of HDAC3 in breast cancer (BC) cells which suggest an oncogenic role for this enzyme. Interestingly, some studies showed that HDAC3 inhibition could be considered as a promising target in breast cancer therapy, and thus far, several inhibitors from different nature have been introduced. In this review, we discussed the function and highlight the existing inhibitors of HDAC3 in BC pathogenesis and therapy.
最近有研究表明，组蛋白去乙酰化酶（HDAC）3 是 HDAC 家族中的一个独特成员，通过改变基因表达和蛋白质活性来引发和促进癌症的发生。HDAC 介导的表观遗传修饰在各种癌细胞中已有很好的研究。最近的研究集中在 HDAC 酶作为癌症治疗的一个可能靶点上。有大量文献报道 HDAC3 在乳腺癌（BC）细胞中的上调，这表明该酶具有致癌作用。有趣的是，一些研究表明，抑制 HDAC3 可以被认为是乳腺癌治疗的一个有前途的靶点，到目前为止，已经引入了几种不同性质的抑制剂。在这篇综述中，我们讨论了 HDAC3 在 BC 发病机制和治疗中的功能，并强调了现有的抑制剂。
